Efficacy of Vastarel MR on silent and symptomatic myocardial ischemia

Giuseppe Camitini, Giuseppe Marazzi, Giuseppe Rosano

Research output: Contribution to journalArticlepeer-review


Despite advances in the medical treatment of myocardial ischemia, a large proportion of patients with coronary artery disease suffer from angina and have silent episodes of myocardial ischemia. Chronic repetitive ischemic episodes may lead to ischemic cardiomyopathy. Trimetazidine, the 3-ketoacyl coenzyme A thiolase inhibitor, is a metabolically active agent that is effective, whether alone or in combination with standard therapy, in reducing myocardial ischemia. It has been shown to reduce daily episodes of both silent and symptomatic myocardial ischemia. These effects, together with those of trimetazidine on myocardial energy production, are likely to reduce the progression of ventricular dysfunction in patients with ischemic cardiomyopathy.

Original languageEnglish
Pages (from-to)27-29
Number of pages3
JournalHeart and Metabolism
Issue number38
Publication statusPublished - 2008


  • Ischemic cardiomyopathy
  • Myocardial energy
  • Silent myocardial ischemia
  • Symptomatic myocardial ischemia
  • Trimetazidine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Efficacy of Vastarel MR on silent and symptomatic myocardial ischemia'. Together they form a unique fingerprint.

Cite this